BNET Industries
Market Cap:$14.7M
Last Fiscal Year Sales:$361.0K
- Public
- US
Dow Jones Description
NovaDel Pharma Inc. is a specialty pharmaceutical company developing oral spray formulations for a broad range of marketed drugs. Our proprietary technology offers, in comparison to conventional oral dosage forms, the potential for faster absorption of drugs into the bloodstream leading to quicker onset of therapeutic effects and possibly lower doses. Oral sprays eliminate the requirement for water or the need to swallow, potentially improving patient convenience and compliance. Our oral spray technology is focused on addressing unmet medical needs for a broad array of existing and future pharmaceutical products. Our most advanced oral spray candidates target angina, nausea, insomnia, migraine headaches and disorders of the central nervous system. We plan to develop these and other products independently and through collaborative arrangements with pharmaceutical and biotechnology companies. Currently, we have eight patents which have been issued in the U.S. and 69 patents which have been issued outside of the U.S. Additionally, we have over 90 patents pending around the world. We look for drug compounds that are off patent or are coming off patent in the near future, and we formulate these compounds in conjunction with our proprietary drug delivery method. Once formulated, we file for new patent applications on these formulated compounds that comprise our product candidates. ...
Interim President & Chief Executive Officer
Steven B. RatoffNumber of Employees 14
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
NovaDel Releases Financial Results for 3Q and 9 Months Ended September 30
-
Hi-Tech Pharmacal to market NovaDel's insomnia spray
-
NovaDel Signs Licensing and Distribution Pact with ECR Pharmaceuticals to Commercialize and Manufacture ZolpiMist
-
PicksThatMove.com Announces Investment Opinion On: Human Genome Science Inc., General Electric...
-
NovaDel Licenses its NitroMist® Lingual Spray to Mist
-
Week of Oct. 19, 2009: Lonza Drops Bid for Patheon; Peregrine Appoints Head of Regulatory...
-
NovaDel Reports Financial Results for Second Quarter and Six
News & Analysis
Filter by
novadel pharma inc. - All News and Analysis
NovaDel Pharma: Won't Be Long Before Big Pharma Partners Come Calling
GT McDuffy submits: Novadel Pharma Inc.NVD recently received FDA approval of its Zolpimist™ zolpidem tartrate 5 mg and 10 mg Oral Spray. Zolpimist™ is intended for the short-term treatment of insomnia characterized by difficulties with sleep initiation. by GT McDuffy
Novadel Longs May Finally Get a Good Night's Sleep
Douglas Cress submits: The FDA has approved NovaDel’s NVD Zolpimist, an oral spray for the short-term treatment of insomnia. Zolpimist contains zolpidem tartrate, the same active ingredient found in Ambien. Until recently, the U.S. patent for zolpidem was held by the French pharmaceutical giant Sanofi-Aventis SNY. In April 2007, the...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Steven B. Ratoff | Interim President & Chief Executive Officer |
| David H. Bergstrom | Coo & Senior Vice President |
| Deni M. Zodda | Chief Business Officer & Senior Vice President |
| Michael E. Spicer | Cfo & Secretary |
| Frank Blondino | Executive Director, Formulation & Process Dev |
| Jay Moorin | |
| Joseph M. Warusz | Principal Accounting Officer |
| Jack J Kornreich | Director |
| Robert F Schaul | Director |
| Robert G. Savage | Director |
| William F. Hamilton | Director |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Charles Nemeroff | Board of Directors |
| J. Jay Lobell | Board of Directors |
| Mark H. Rachesky | Board of Directors |
| Mark J Baric | Board of Directors |
| Tom Bonney | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| NovaDel Pharma Inc. | Interim President & Chief Executive Officer | Current |
| Proquest Investments | Venture Partner | Current |
| Axonyx Inc. | Chairman | Current |
| NovaDel Pharma Inc. | Director and Chairman of The Board, Interim | Current |
| Integrateir | Chairman of the Board | Current |
| Doctations Inc. | Director | Current |
| NovaDel Pharma Inc. | Director | Current |
| Axonyx Inc. | Board of Directors | Current |
| Tptx, Inc. | Board of Directors | Current |
| Progressive Brands, Inc. | Board of Directors | Current |
| CIMA Labs Inc. | Interim CEO | Former |
| Macromed, Inc. | CEO | Former |
| Macromed, Inc. | President | Former |
| Brown-Forman Corporation | Chief Financial Officer | Former |
| Bristol-Myers Squibb Company | Cfo | Former |
| Brown-Forman Corporation | Executive Vice President | Former |
| Bristol-Myers Squibb Company | Senior Vice President | Former |
| ProQuest Company | Venture Partner | Former |
| Arthur Andersen LLP | NA | Former |
| Arthur Anderson & Co. | Former | |
| CIMA Labs Inc. | Chairman | Former |
| Linux Gold Corp | Chairman of the Board | Former |
| University of Michigan | M.B.A. | Former |
| Boston University | B.S. In Business Administration | Former |
| Organization | Position | Status |
|---|---|---|
| Integrateir | Chief Operating Officer & Senior Vice President | Current |
| Linux Gold Corp | Chief Operating Officer & Senior Vice President | Current |
| Teryl Resources Corp | Chief Operating Officer | Current |
| NovaDel Pharma Inc. | Coo & Senior Vice President | Current |
| Guilford Pharmaceuticals, Inc. | Vice President of Pharmaceutical and Chemical Development | Former |
| Hoechst Marion Roussel | Former | |
| Analytical Sciences | Director | Former |
| University of Utah | Ph.D. In Pharmaceutics | Former |
| University of Michigan-Ann Arbor | M.S. In Pharmaceutical Chemistry | Former |
| University of Michigan | M.S. In Pharmaceutical Chemistry | Former |
| Ferris State University | B.S. In Pharmacy | Former |
| Organization | Position | Status |
|---|---|---|
| NovaDel Pharma Inc. | Chief Business Officer & Senior Vice President | Current |
Mr. Spicer joins NovaDel as Chief Financial Officer. Mr. Spicer was most recently the Chief Financial Officer of Orchid Biosciences, Inc, a leading provider of identity genetics testing services. At Orchid he played a key role in the successful capital restructuring of the company and its achievement of quarterly operating profitability. Previously, Mr. Spicer served as Vice President, Chief Financial Officer of Lifecodes Corporation from 1998 until it was acquired by Orchid. His background prior to Lifecodes includes over 20 years of finance and accounting experience with White River Corporation, The Chinet Company, Kraft General Foods and Deloitte & Touche. Mr. Spicer is a Certified Public Accountant, and holds an undergraduate degree in Accounting from the University of Virginia and a MBA from Harvard University.
| Organization | Position | Status |
|---|---|---|
| Jml Resources Ltd | Chief Financial Officer | Current |
| Teryl Resources Corp | Chief Financial Officer | Current |
| NovaDel Pharma Inc. | Cfo & Secretary | Current |
| Linux Gold Corp | Chief Financial Officer & Corporate Secretary | Current |
| Integrateir | Chief Financial Officer | Current |
| White River | Current | |
| Orchid Biosciences, Inc | Chief Financial Officer | Former |
| Orchid Co | Former | |
| Harvard University | M.B.A | Former |
| University of Virginia | Undergraduate Degree In Accounting | Former |
| Organization | Position | Status |
|---|---|---|
| NovaDel Pharma Inc. | Executive Director, Formulation & Process Dev | Current |
| Organization | Position | Status |
|---|---|---|
| NovaDel Pharma Inc. | Current |
| Organization | Position | Status |
|---|---|---|
| NovaDel Pharma Inc. | Principal Accounting Officer | Current |
| Organization | Position | Status |
|---|---|---|
| Emory University School of Medicine | Reunette W. Harris Professor | Current |
| Pfizer Inc. | Current | |
| Organon Inc. | Current | |
| Wyeth-Ayerst | Current | |
| Acadia, Inc | Current | |
| Emory University School of Medicine | Chairman of the Department of Psychiatry and Behavioral Sciences | Current |
| Linux Gold Corp | Director | Current |
| Neurosciencecme | Board of Directors | Current |
| Integrateir | Director | Current |
| Jml Resources Ltd | Director | Current |
| Teryl Resources Corp | Director | Current |
| Martin Midstream Partners LP | Director | Current |
| NovaDel Pharma Inc. | Board of Directors | Current |
| The American College of Psychiatrists | President | Former |
| American College of Neuropsychopharmacology | President | Former |
| The National Institute of Mental Health | Former | |
| ACADIA Pharmaceuticals Inc. | Former | |
| National Aeronautics and Space Administration | Former | |
| Emory University | Professor and Chairman | Former |
| Cypress Bioscience, Inc. | Chairman | Former |
| The University of North Carolina at Chapel Hill | PhD | Former |
| The University of North Carolina | M.D. | Former |
| Northeastern University | M.S. | Former |
| Organization | Position | Status |
|---|---|---|
| Paramount Acquisition Corp | Chief Executive Officer | Current |
| Paramount Biosciences, LLC | Chief Operating Officer | Current |
| Chem Rx | Chief Executive Officer, Secretary and Director | Current |
| NovaDel Pharma Inc. | Board of Directors | Current |
| Tikvah Therapeutics, Inc. | Director | Current |
| Balboa Biosciences Inc. | Director | Current |
| Innovive Pharmaceuticals, Inc. | Director | Current |
| Integrateir | Director | Current |
| Martin Midstream Partners LP | Director | Current |
| Teryl Resources Corp | Director | Current |
| Linux Gold Corp | Director | Current |
| Velcera Pharmaceuticals Inc. | President and Secretary | Former |
| Paramount Biosciences, LLC | President | Current |
| Eisner LLP | Auditor | Former |
| Paramount Acquisition Corp | Member of the Board of Directors | Former |
| Yale Law School | Jd | Former |
| Erasmus University | M.D. | Former |
| Stanford University | Mba Degree | Former |
| Queens College | BA | Former |
| Harvard Medical School | Former |
| Organization | Position | Status |
|---|---|---|
| NovaDel Pharma Inc. | Director | Current |
| Organization | Position | Status |
|---|---|---|
| NationsHealth, Inc. | Co-Founder | Current |
| East Coast Diabetic Supply | Co-Founder | Current |
| Neose Technologies, Inc. | Board of Directors | Current |
| Loral Space & Communications, Inc. | Chairman | Current |
| Telesat Canada | Non-Executive Chairman of the Board | Current |
| Leap Wireless International, Inc. | Member and Chairman | Current |
| NationsHealth, Inc. | Board of Directors | Current |
| Keryx Biopharmaceuticals, Inc. | Director | Current |
| NovaDel Pharma Inc. | Board of Directors | Current |
| Lions Gate Entertainment Corp. | Board of Directors | Current |
| Emisphere Technologies, Inc. | Board of Directors | Current |
| East Coast Diabetic Supply | Board of Directors | Current |
| Leap Wireless International, Inc. | Board of Directors | Former |
| Stanford University School of Medicine | M.D. | Former |
| Stanford University | M.B.A. | Former |
| University of Pennsylvania | BS | Former |
Array
| Organization | Position | Status |
|---|---|---|
| Cenerx Biopharma, Inc. | Co-Founder | Current |
| Cenerx Biopharma, Inc. | Board of Directors | Current |
| Martin Midstream Partners LP | Director | Current |
| NovaDel Pharma Inc. | Board of Directors | Current |
| Integrateir | Director | Current |
| Linux Gold Corp | Board of Directors | Current |
| Concert Technologies | Board of Directors | Current |
| Seer Technologies | Chief Financial and Administrative Officer | Former |
| Clarion University | M.B.A. | Former |
| Wharton Graduate School of the University of Pennsylvania | M.B.A. | Former |
| Clarion University | B.S. | Former |
| Organization | Position | Status |
|---|---|---|
| NovaDel Pharma Inc. | Director | Current |
| Organization | Position | Status |
|---|---|---|
| Vela Pharmaceuticals, Inc. | Current | |
| EpiCept Corporation | Non-Executive Chairman of the Board | Current |
| Noven Pharmaceuticals, Inc. | Chairperson | Current |
| JDS Pharmaceuticals, LLC | Chairperson | Current |
| The Medicines Company | Director | Current |
| Angiox | Board of Directors | Current |
| Noven Pharmaceuticals, Inc. | Director | Current |
| NovaDel Pharma Inc. | Director | Current |
| Johnson & Johnson | President | Former |
| The Group Inc. | President | Former |
| Pharmacia Corporation | President | Former |
| Johnson & Johnson | Vice President Sales & Marketing | Former |
| The Medicines Company | Vice President | Former |
| Pharmacia Corporation | Group Vice President | Former |
| Johnson & Johnson | Chairman | Former |
| The Group Inc. | Chairman | Former |
| The Medicines Company | Chair | Former |
| EpiCept Corporation | Board of Directors | Former |
| Rutgers University | MBA | Former |
| Upsala College | B.S. In Biology | Former |
With over 20 years of experience in financial, operations, technology and business development areas, Tom brings an informed, broad, and deep level of expertise to our client's strategic and tactical issues across many industry groups (manufacturing, retail, professional services, technology, and pharmaceuticals). He is a recognized expert on middle market operations, integration of acquisitions, European/US business relationships, and business strategies. Prior to CMF Associates, Tom led a profitable high technology consultancy practice, Polaris Consulting & Information Technologies, and worked at Deloitte & Touche in their accounting and audit practices in Philadelphia and London. Tom also serves as the Audit Committee Chairman at NovaDel Pharmaceuticals (AMEX:NVD). In addition, he serves as an adjunct professor at Temple University where he teaches business strategy and continues to foster entrepreneurship at local universities as a judge for business plan competitions at Temple University and Drexel University. He speaks frequently on various business topics and has had several articles published on practical applications of information technology in local magazines. Tom is a member of the Pennsylvania Institute of Certified Public Accountants and graduated Magna Cum Laude and was a University Scholar at Penn State University.
| Organization | Position | Status |
|---|---|---|
| Cmf Associates, LLC | President | Current |
| Cmf Associates, LLC | Founder and Managing Director | Current |
| Temple University | Adjunct Professor | Current |
| Pennsylvania Institute of Certified Public Accountants | Board of Directors | Current |
| Linux Gold Corp | Director | Current |
| Teryl Resources Corp | Director | Current |
| Jml Resources Ltd | Director | Current |
| Integrateir | Director | Current |
| Martin Midstream Partners LP | Director | Current |
| NovaDel Pharma Inc. | Board of Directors | Current |
| Polaris Consulting | Partner | Former |
| Information Technologies, Inc. | Partner | Former |
| MRI | Former | |
| CDI Corp. | Former | |
| Deloitte & Touche LLP | Former | |
| The Pennsylvania State University | B.S. In Accounting | Former |
| Organization | Position | Status |
|---|---|---|
| Yaupon Therapeutics | Landau Professor of Management and Technology | Current |
| Mentortech Ventures | Chairman | Current |
| Martin Midstream Partners LP | Director | Current |
| Linux Gold Corp | Director | Current |
| Teryl Resources Corp | Director | Current |
| Integrateir | Director | Current |
| Neuronyx | Director | Current |
| NovaDel Pharma Inc. | Director | Current |
| Jml Resources Ltd | Director | Current |
| Yaupon Therapeutics | Director | Current |
| Neuro Diagnostic Devices | Board of Directors | Current |
| University of Pennsylvania | Faculty | Former |
| The Wharton School of the University of Pennsylvania | Director | Former |
| Neose Technologies, Inc. | Director | Current |
| The London School of Economics | Ph.D. In Applied Economics | Former |
| The London School of Economics | M.S. In Chemical Engineering | Former |
| University of Pennsylvania | M.B.A. | Former |
| The London School of Economics | B.S. | Former |
Executive News
-
TV boosts Lions Gate quarterly earnings
-
Television delivers strong quarter for Lions Gate
-
NovaDel Receives Approval to Issue up to 12.0 Million Shares over the Next 12 Months
-
NovaDel Receives Approval to Issue up to 12.0 Million Shares over the Next 12 Months
-
Conflict With My Interests
-
Double Standard at Emory?
-
NovaDel Receives Commitment of Investment Fund to Purchase up to 13.0 Million Shares over the...
-
NovaDel Receives Commitment of Investment Fund to Purchase up to 13.0 Million Shares over the Next 12 Months
-
NovaDel Receives Commitment of Investment Fund to Purchase up to 13.0 Million Shares over the Next 12 Months
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- The 10 Weirdest Drug Stories of the Month 3 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes

